Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Late annual account NBB
Fiscal year 2022 was filed 554 days after the legal deadline.
-
Annual account missing NBB
Fiscal year 2023 was expected before 31 July 2024 and has not been filed.
Financials
Financial year 2022
CellCarta Biosciences from Charleroi, company number BE0661567021, closed financial year 2022 with a result of € 865,963 after tax. For that financial year CellCarta Biosciences recorded a gross margin of € 6 million and equity of € 607,231. Compared with financial year 2021, the result moved from € 1 million to € 865,963. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on February 4, 2025.
€ 607,231
▲ € 865,963 vs 2021
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 865,963
▼ 16% vs 2021
Profit after tax over the fiscal year.
€ 353,120
▲ 53% vs 2021
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2022. Retained profit grew to € 545,731.
People and assets in 2022
48.2
▲ 6 vs 2021
Average over the fiscal year, from the social balance sheet.
€ 4.8 million
▲ 29% vs 2021
€ 99,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 68,812
▲ 85% vs 2021
Book value of vehicles, furniture and equipment.
Debts at end 2022
€ 2 million
▲ 28% vs 2021
€ 203,086 is repaid this year. At this pace the long-term loan is gone in ≈ 10 years.
€ 1.9 million
▲ 31% vs 2021
Supplier invoices still open on the last day of the fiscal year.
€ 833,860
▲ 31% vs 2021
Taxes, VAT and social contributions still to pay.
| 2020 | 2021 | 2022 | Change 2021 → 2022 | |
|---|---|---|---|---|
| Gross margin | € 3,096,958 | € 6,845,829 | € 6,020,150 | ▼ 12% |
| Profit after taxes | € 215,269 | € 1,034,123 | € 865,963 | ▼ 16% |
| Equity | € -1,292,855 | € -258,732 | € 607,231 | ▲ € 865,963 |
| Total debts | € 8,325,471 | € 17,265,492 | € 27,085,118 | ▲ 57% |
| Cash | € 235,232 | € 231,467 | € 353,120 | ▲ 53% |
| Retained profit | € -1,354,355 | € -320,232 | € 545,731 | ▲ € 865,963 |
| Bank debt | € 753,982 | € 1,553,741 | € 1,995,574 | ▲ 28% |
| Balance sheet total | € 7,032,616 | € 17,006,761 | € 27,692,349 | ▲ 63% |
| Employees (FTE) | 31.1 | 42.2 | 48.2 | ▲ 6 |
Key figures of CellCarta Biosciences, fiscal years 2020 to 2022, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2023 has not been filed yet; it was expected before 31 July 2024.
What happened to CellCarta Biosciences?
What happened at CellCarta Biosciences in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Maurice Tenney III stepped down as director. NBB
- Anthony Mattacchione stepped down as director. NBB
- David Spaight stepped down as director. NBB
- New annual accounts for financial year 2022: profit of € 865,963 (▼ 16% vs 2021). filed late Source: NBB ↗
- Martin Leblanc stepped down as director. NBB
- Maurice Tenney III became a director. NBB
- Anthony Mattacchione became a director. NBB
- David Spaight became a director. NBB
In short
From € 215,269 profit in 2020 to € 865,963 profit in 2022.
Paid € 3,556 in corporate taxes since 2020.
Best year ever: 2021, with € 1 million profit.
On average € 124,900 of value added per employee in 2022.
Management
Directors
According to the 2022 annual accounts
Anthony Mattacchione
Director
since 2021 · until 2025
since 2019 · until 2025
Martin Leblanc
Director
since 2019 · until 2023
Maurice Tenney III
Director
since 2023 · until 2026
Establishments
Establishment units
Physical locations of this company
Rue Adrienne Bolland 8 box 2
6041 Charleroi
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0661.567.021
- VAT number
- BE 0661.567.021
- Registered office
- Rue Adrienne Bolland 8 bus 2, 6041 Charleroi
- Names & denominations
- CellCarta Biosciences
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 18 August 2016
- Peppol
- Active · Active since 14 Oct 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied